NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37 | +2.8% | 61,886 | 0.0% | 0.00% | – |
| Q2 2023 | $36 | -16.3% | 61,886 | 0.0% | 0.00% | – |
| Q1 2023 | $43 | -69.3% | 61,886 | 0.0% | 0.00% | -100.0% |
| Q4 2022 | $140 | -99.9% | 61,886 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $198,000 | -37.1% | 61,886 | +5.8% | 0.00% | -33.3% |
| Q1 2022 | $315,000 | -50.0% | 58,500 | +25.5% | 0.00% | -50.0% |
| Q4 2021 | $630,000 | +72.6% | 46,600 | +129.6% | 0.01% | +100.0% |
| Q3 2021 | $365,000 | +4.9% | 20,300 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $348,000 | -14.3% | 20,300 | 0.0% | 0.00% | -25.0% |
| Q1 2021 | $406,000 | +3.8% | 20,300 | -11.7% | 0.00% | 0.0% |
| Q4 2020 | $391,000 | -12.3% | 23,000 | -14.5% | 0.00% | -20.0% |
| Q3 2020 | $446,000 | -28.4% | 26,900 | 0.0% | 0.01% | -28.6% |
| Q2 2020 | $623,000 | +29.8% | 26,900 | 0.0% | 0.01% | 0.0% |
| Q1 2020 | $480,000 | -24.6% | 26,900 | -8.8% | 0.01% | 0.0% |
| Q4 2019 | $637,000 | +108.2% | 29,500 | +75.6% | 0.01% | +75.0% |
| Q3 2019 | $306,000 | -48.8% | 16,800 | 0.0% | 0.00% | -42.9% |
| Q2 2019 | $598,000 | +6.0% | 16,800 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $564,000 | +2.2% | 16,800 | 0.0% | 0.01% | -12.5% |
| Q4 2018 | $552,000 | -48.0% | 16,800 | -3.4% | 0.01% | -38.5% |
| Q3 2018 | $1,061,000 | -28.7% | 17,400 | -43.0% | 0.01% | -27.8% |
| Q2 2018 | $1,489,000 | -76.4% | 30,500 | -48.7% | 0.02% | -76.3% |
| Q1 2018 | $6,312,000 | +124.9% | 59,405 | +26.4% | 0.08% | +130.3% |
| Q4 2017 | $2,807,000 | +148.8% | 47,000 | 0.0% | 0.03% | +135.7% |
| Q3 2017 | $1,128,000 | +22.7% | 47,000 | 0.0% | 0.01% | +16.7% |
| Q2 2017 | $919,000 | -16.7% | 47,000 | 0.0% | 0.01% | -14.3% |
| Q1 2017 | $1,103,000 | +91.2% | 47,000 | 0.0% | 0.01% | +100.0% |
| Q4 2016 | $577,000 | -32.7% | 47,000 | -5.8% | 0.01% | -36.4% |
| Q3 2016 | $857,000 | +45.0% | 49,900 | +20.2% | 0.01% | +37.5% |
| Q2 2016 | $591,000 | +3.5% | 41,500 | 0.0% | 0.01% | +14.3% |
| Q1 2016 | $571,000 | -18.3% | 41,500 | 0.0% | 0.01% | -22.2% |
| Q4 2015 | $699,000 | +53.6% | 41,500 | 0.0% | 0.01% | +50.0% |
| Q3 2015 | $455,000 | +42.6% | 41,500 | +62.7% | 0.01% | +50.0% |
| Q2 2015 | $319,000 | – | 25,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HARVEY CAPITAL MANAGEMENT INC | 598,400 | $10,083,000 | 3.98% |
| Opus Point Partners Management, LLC | 348,583 | $5,874,000 | 3.88% |
| Camber Capital Management LP | 3,500,000 | $58,975,000 | 3.81% |
| 1492 Capital Management LLC | 180,601 | $3,043,000 | 2.21% |
| Virtus ETF Advisers LLC | 38,260 | $645,000 | 1.77% |
| Cormorant Asset Management, LP | 765,156 | $12,893,000 | 1.54% |
| Rhenman & Partners Asset Management AB | 581,000 | $9,790,000 | 1.48% |
| Granahan Investment Management | 2,082,155 | $35,084,000 | 1.21% |
| BRIDGER MANAGEMENT, LLC | 1,563,862 | $26,351,000 | 0.87% |
| RICE HALL JAMES & ASSOCIATES, LLC | 899,531 | $15,157,000 | 0.87% |